Amgen: Wells Fargo raises target price
(CercleFinance.com) - Wells Fargo confirms its "overweight" rating on Amgen shares, while raising its target price for them from $265 to $320, explaining that the pharmaceutical group's emerging pipeline gives it greater confidence in its long-term growth.
"HZNP deal and accretion due to this could help support near-term growth for the company. Plenty of catalysts make it cleaner story in 2024," the broker says, which also sees numerous catalysts that make it a clearer story in 2024.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
"HZNP deal and accretion due to this could help support near-term growth for the company. Plenty of catalysts make it cleaner story in 2024," the broker says, which also sees numerous catalysts that make it a clearer story in 2024.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.